1

2

3

4 Gastrointestinal absorption of pimozide is enhanced by inhibition of P-glycoprotein.

5

6

7 Hiroki Morishita^{1,2}¶, Kozue Okawa³¶, Misaki Ishii^{3&}, Kenta Mizoi³, Hiroshi Arakawa^{4&},

8 Kentaro Yano³¶, Takuo Ogihara^{1,3,*}

9

10 ¹ Laboratory of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences,

11 Takasaki University of Health and Welfare, Nakaorui-machi, Takasaki, Gunma, Japan

12

13 ² Department of Pharmacy, Saiseikai Maebashi Hospital, Kamishinden-machi,

14 Maebashi, Gunma, Japan

15

16 ³ Laboratory of Biopharmaceutics, Faculty of Pharmacy, Takasaki University of Health

17 and Welfare, Nakaorui-machi, Takasaki, Gunma, Japan

18

19 ⁴ Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences,

20 Kanazawa University, Kakuma-machi, Kanazawa, Japan

21

22

23 *Corresponding author

24 E-mail: togihara@takasaki-u.ac.jp (TO)

25

26

27 [†] These authors contributed equally to this work.

28 [&] These authors also contributed equally to this work.

29

30

31

32

33

34

35

36

Abstract

Following the death due to cardiac arrest of a patient taking pimozone, sertraline and aripiprazole antipsychotic/antidepressant combination therapy, a role of drug-drug interaction was suggested. Here, we investigated P-glycoprotein (P-gp)-mediated interaction among the three drugs using in vitro methods. Sertraline or aripiprazole significantly increased the permeability of pimozone in Caco-2 cell monolayers. ATPase assay indicated that pimozone is a P-gp substrate, and might act as a P-gp inhibitor at higher concentrations. The values of the kinetic parameters of carrier-mediated efflux, calculated from the concentration dependence of pimozone efflux from LLC-GA5-COL150 cells expressing human P-gp, were as follows: maximum transport rate (J_{max}) = 84.9 ± 8.9 pmol/min/mg protein, half-saturation concentration (K_t) = 10.6 ± 4.7 μ M, first-order rate constant (k_d) = 0.67 ± 0.14 pmol/min/mg protein. Further, the efflux ratio of pimozone in LLC-GA5-COL150 cells was significantly decreased in the presence of sertraline or aripiprazole. These results indicate that pimozone is a substrate of P-gp, and its efflux is inhibited by sertraline and aripiprazole. Thus, P-gp inhibition by sertraline and/or aripiprazole may alter the gastrointestinal permeability of co-administered pimozone, resulting in an increased blood concentration of pimozone, which may increase the likelihood of pimozone's known life-threatening side effect of QT prolongation.

Introduction

Pimozide is an antipsychotic used to treat schizophrenic and pediatric autistic disorders.

However, one of its major side effects is QT prolongation [1], because it is a strong antagonist of the alpha subunit of a potassium ion channel (hERG) [2] and this action causes a significant prolongation of QT intervals [3]. Several antidepressants are restricted for use in combination with pimozide, because of the increased risk of this side effect [4]. For example, the combination of pimozide and sertraline is contraindicated because it leads to an increased blood concentration of pimozide, thus increasing the risk of QT prolongation. Nevertheless, a case has been reported in which a male child administered pimozide together with sertraline and aripiprazole died due to cardiac arrest [5]. Pimozide is a substrate of the metabolic enzymes CYP3A4, 2D6, and 1A2, and aripiprazole is a substrate of 3A4 and 2D6 [6], while sertraline is a substrate of 2C19, 2C9, 2B6, and 3A4, and a mild to moderate inhibitor of CYP2D6 [7]. Therefore, it had been suspected that interaction among those drugs would be due to inhibition of CYP-mediated pimozide metabolism by sertraline and/or aripiprazole. On the other hand, Alderman reported that the C_{max} and AUC of pimozide were increased by 35% and 37%, respectively, with no significant difference in blood half-life, when the drug was used in combination with sertraline [8]. In pharmacokinetics, blood half-life is inversely proportional to clearance; in other words, if hepatic CYP3A4 and/or CYP2D6 metabolism were inhibited by sertraline, the blood half-life of pimozide should be

prolonged. This suggests that a drug interaction mechanism(s) other than inhibition of CYP3A4 and/or CYP2D6 is involved. We speculated that the drug transporter P-glycoprotein (P-gp) might be an interaction site.

P-gp is a member of the ATP-binding cassette superfamily, and is mainly localized at the intestine, blood-brain barrier, adrenal gland, enterocytes, hepatocytes, placenta and renal proximal tubules in humans [9]. P-gp is responsible for the efflux of many xenobiotics and plays major roles in drug absorption, distribution and excretion. In the intestine, P-gp mediates the efflux of its substrates, restricting the absorption of many xenobiotics, including drugs [10–13]. Recent studies show that sertraline, aripiprazole, and several of their metabolites have a P-gp-inhibitory effect [14–16], whereas pimozone is not known to be a P-gp substrate. The bioavailability of pimozone is limited (about 50%) [17]. Therefore, if pimozone is a P-gp substrate, there is a possibility that its absorption could be increased when it is used in combination with P-gp inhibitors. In order to test this idea, we examined whether pimozone is a P-gp substrate, and whether its gastrointestinal permeability might be influenced by sertraline and/or aripiprazole by means of a series of in vitro studies.

Materials and Methods

Chemicals

Pimozide was purchased from Santa Cruz Biotechnology (Dallas, TX). Sertraline hydrochloride, aripiprazole and verapamil hydrochloride were purchased from Wako Pure Chemical Industries (Osaka, Japan). All other reagents were commercial products of reagent grade.

Cell culture

Caco-2 cells, a human colon epithelial cancer cell line frequently used as an in vitro intestinal model, were purchased from the American Type Culture Collection (Rockville, MD, USA). They were cultured, passaged and grown as described previously [19] in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 0.1 mg/ml streptomycin, and 1.0 % nonessential amino acids, at 37°C in an atmosphere of 5% CO₂ in air. The cells were seeded on Transwell filter membrane inserts (Costar, Bedford, MA, USA) at a density of 6 × 10⁴ cells/cm². The culture medium was replaced with fresh medium every second or third day and Caco-2 cell monolayers grown for 21 days were used for the transport studies. Transepithelial electrical resistance (TEER) was measured using a Millicell-ERS resistance system (Millipore, Bedford, MA, USA). Cell monolayers used for transport studies had TEER values of 800 to 1000 Ω·cm².

LLC-GA5-COL150 cells, a derivative of kidney epithelial cell line LLC-PK1 expressing human P-gp on the apical membrane, were obtained from Riken Gene Bank (Tsukuba, Japan). They were cultured, passaged and grown as described previously [20] in Medium 199 supplemented with

10% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin and 150 ng/mL colchicine, at 37°C in an atmosphere of 5% CO₂ in air. The cells were seeded on Transwell filter membrane inserts (Costar, Bedford, MA, USA) at a density of 2.5×10^5 cells/cm² for transport studies [20], and seeded on 24-well cell culture plates (Corning, NY, USA) at a density of 1.5×10^5 cells/cm² for efflux assays [21]. The culture medium was replaced with fresh medium every second or third day. Cells were grown for 7 days and used for experiments. One day prior to experiments, the medium was changed to Medium 199 without colchicine. Cell monolayers with TEER values of 300 to 600 Ω·cm² were used for transport studies.

Transport experiments

In the transport studies with Caco-2 cell monolayers, the transport medium on the apical side consisted of Hanks' balanced salt solution (HBSS) with 10 mM 2-morpholinoethanesulfonic acid (MES) (pH 6.5) and that on the basal side consisted of HBSS with 10 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES) (pH 7.4). Test chemicals were dissolved in dimethyl sulfoxide (DMSO) and diluted with transport medium (the final DMSO concentration was 1%). Caco-2 cell monolayers were preincubated with the transport medium for 20 min at 37°C. Transport experiments were initiated by adding the transport medium containing pimozone (10 µM) to the donor side, while the receiver side was filled with transport medium. The concentration of

pimozide was chosen with reference to the clinical dose of 1 mg dissolved in 250 mL of water [22], which corresponds to a concentration of 9 μ M. Inhibitor was added to both sides during inhibition studies. Sertraline (500 μ M), aripiprazole (15 μ M) and verapamil were used as inhibitors (verapamil as a positive control). The tested concentrations of sertraline and aripiprazole were chosen in the same manner as described above, based on the calculation that the clinical doses of sertraline (25 mg) and aripiprazole (3 mg) in 250 mL of water would correspond to concentrations of 292 μ M and 27 μ M, respectively. Samples were collected at 20, 40, 60, 90 and 120 min, and replaced with equal amounts of transport medium. In the transport studies with LLC-GA5-COL150 cell monolayers, the transport medium on both sides consisted of HBSS with 10 mM HEPES (pH 7.4). Inhibitors were added to the donor side and transport experiments were initiated in the same manner. Samples were collected at 15, 30, 45 and 60 min, and replaced with equal amounts of transport medium. The time course of drug transport in the apical (A) to basal (B) direction (A to B) and that in the opposite direction (B to A) were observed at 37°C. The permeability (P_{app}) across cell monolayers was evaluated by dividing the slope of the experimental time course in the A-to-B or B-to-A direction by the concentration on the donor side and is represented as $P_{app\ AtoB}$ or $P_{app\ BtoA}$, respectively. The efflux ratio (ER) was calculated by dividing $P_{app\ BtoA}$ by $P_{app\ AtoB}$.

ATPase assay

The SB-MDR1 PREDEASY™ ATPase Kit, including P-gp-expressing membrane vesicles, was purchased from SOLVO Biotechnology (distributed by KAC Co., Ltd., Kyoto, Japan). This assay kit is designed to measure the interaction of test drugs with P-gp. ATPase assay was conducted according to the manufacturer's instructions and a previous report [18]. Inorganic phosphate liberated by ATP hydrolysis was detected by colorimetric reaction. The optical density (OD) was measured at 590 nm with a microplate reader, Sunrise™ Rainbow (TECAN, Kanagawa, Japan).

Efflux study

To investigate the involvement of P-gp in pimozone efflux transport, efflux studies with LLC-GA5-COL150 cells were performed. Cells seeded on 24-well cell culture plates were washed twice with ice-cold Dulbecco's phosphate-buffered saline (-) (D-PBS(-)), and pretreated with 300 µL of ice-cold Opti-MEM containing 0.01 to 100 µM pimozone for 30 min on ice (4°C). The Opti-MEM was removed, and the cells were washed twice with ice-cold D-PBS(-). Experiments were initiated by adding pimozone-free Opti-MEM to each well and incubating the plates at 37°C. After 10 min, transport was stopped by washing each well three times with ice-cold D-PBS(-), and the cells were lysed by adding 200 µL of 0.1 N NaOH solution. Cell lysates were used for protein determination and measurement of pimozone concentration. Protein was determined colorimetrically using DC™ Protein Assay (BIO-RAD, Hercules, CA), based on absorbance measurement at 700 nm with a microplate

reader, Sunrise Rainbow RC (Tecan, Kanagawa, Japan). An aliquot of cell lysate was mixed with 300 μ L of ethyl acetate for 10 min in the cold, then 100 μ L of the organic phase was moved to a new tube and evaporated. The residue was dissolved in 300 μ L of mobile phase. All samples were applied to MultiScreen® Solvent Filter Plates 0.45 μ m Low-Binding Hydrophilic PTFE (Merck, Ireland) and centrifuged at 3,500 rpm for 20 min at 4°C. Filtered samples were collected in a 96-well microplate (Asone, Japan), and pimozone concentration was determined by triple quadrupole liquid chromatography mass spectrometry (LC-MS/MS) as described below. Efflux rate was calculated according to the following equation.

$$\text{Efflux rate} = (X_0 - X_1) / \text{incubation time}$$

Where X_0 is pimozone concentration per protein amount before incubation and X_1 is that after incubation. Therefore, $X_0 - X_1$ is the net transport of pimozone from LLC-GA5-COL150 cells.

Kinetic analysis

To estimate the kinetic parameters of carrier-mediated transport in the efflux assays, the transport rate (J) was fitted to the following equation (1), containing saturable and nonsaturable-linear terms, by using the nonlinear least-square regression analysis program, MULTI, as previously reported [23].

$$J = J_{\max} \times S / (K_t + S) + k_d \times S \quad (1)$$

Where $J_{\max}$ is the maximum transport rate for the carrier-mediated transport, S is the substrate concentration, K_t is the half-saturation concentration, and k_d is the first-order rate constant.

Measurement of pimozone

Concentrations of pimozone were determined by LC-MS/MS analysis. Pimozone samples (10 μ L) were injected into an HPLC system (LC-20A system, Shimadzu, Kyoto, Japan) equipped with a CAPCELL PAK C18 MGIII / 3 μ m column (ϕ 2.0 $\times$ 50 mm, Shiseido Co. Ltd., Tokyo, Japan). The mobile phase consisted of a mixture of acetonitrile containing 0.1% formic acid (organic solvent phase) and distilled water containing 0.1% formic acid (water phase) (50 : 50). The flow rate was 0.1 mL/min, at 40°C. Analytes were detected using a quadrupole mass spectrometer (LCMS-2010EV, Shimadzu) fitted with an electrospray ionization source. Analytes were detected in the positive mode, and the protonated molecular ion of pimozone was monitored at $m/z = 109.05$.

Statistical analysis

Kinetic parameters are presented as mean $\pm$ standard deviation (S.D.). Other data are presented as mean $\pm$ standard error of the mean (S.E.M.). Statistical analysis of kinetic parameters was performed by means of Dunnett's t -test. A difference between means was considered to be significant when the P value was less than 0.05.

Results

Transport study across Caco-2 cell monolayers

The P_{app} of pimozone in the A-to-B direction in the presence of sertraline was 5.9-fold higher than that in the absence of sertraline. The P_{app} in the B-to-A direction was decreased by sertraline, aripiprazole and verapamil, and sertraline had the greatest effect (Fig 1A). Overall, the addition of sertraline, aripiprazole and verapamil decreased the efflux ratio to 2.9 %, 60.6 % and 43.9 % respectively, compared with pimozone alone (Fig 1B).

Fig 1. Effects of sertraline, aripiprazole and verapamil on pimozone transport across Caco-2 cell monolayers.

The permeability of pimozone at a concentration of 10 μ M was measured in Caco-2 cell monolayers in the absence or presence of sertraline, aripiprazole or verapamil. Bars represent P_{app} of pimozone under each condition (Fig 1A). The efflux ratio of pimozone was calculated from P_{app} under each condition (Fig 1B). Data are shown as mean $\pm$ SEM (n = 3). P : Pimozone 10 μ M. S : Sertraline 500 μ M. A : Aripiprazole 15 μ M. V : Verapamil 100 μ M . **, $p < 0.01$ compared with pimozone.

ATPase assay for P-gp substrate

We investigated the pimozone concentration-sensitive ATPase activity of P-gp (Fig 2).

Concentration-dependent elevation of ATPase activity was initially observed, though concentrations of pimozone over about 10 μ M decreased the ATPase activity.

Fig 2. ATPase activity of pimozone.

The results of ATPase activity assay are shown. Solid circles show activation study ($n = 2$) and open squares show inhibition study ($n = 2$). The black line represents the average and the gray line is the fitted curve. Data are given as relative activity (% of control). The pimozone concentration range is from 0.04 μ M to 100 μ M.

Efflux study of pimozone

The concentration dependence (in the range of 0.01 to 100 μ M) of pimozone efflux from

LLC-GA5-COL150 cells is shown in Fig 3. The J_{max} , K_t and k_d values estimated from the efflux assay

data according to the equation (1) given in Materials and Methods were 84.9 ± 8.9 pmol/min/mg

protein, 10.6 ± 4.7 μ M and 0.67 ± 0.14 pmol/min/mg protein, respectively.

Fig 3. P-gp-mediated efflux transport of pimozone in LLC-GA5-COL150 cells.

The efflux rate of pimoziide from LLC-GA5-COL150 cells are shown. The black line represents the efflux rate of pimoziide from LLC-GA5-COL150 cells. The broken lines represent the saturable (· · · ·) and non-saturable (- - - -) transport components. The pimoziide concentration range is from 0.01 μ M to 100 μ M.

Transport study across P-gp-expressing LLC-GA5-COL150 cell monolayers

Sertraline and aripiprazole significantly decreased the efflux ratio in LLC-GA5-COL150 cell monolayers to 11.0 and 21.9 % of the control, respectively, compared with pimoziide alone (Fig 4).

Fig 4. Efflux ratio of pimoziide in LLC-GA5-COL150 cell monolayers.

The values of the efflux ratio of pimoziide in the absence or presence of sertraline, aripiprazole or verapamil in LLC-GA5-COL150 cell monolayers are shown. Data are shown as mean $\pm$ SEM (n = 5~6). Values were normalized to the control. P : Pimoziide 10 μ M. S : Sertraline 500 μ M. A : Aripiprazole 15 μ M. V : Verapamil 100 μ M. *, $p < 0.05$; **, $p < 0.01$ compared with pimoziide.

Discussion

253 To evaluate the possibility of drug-drug interaction of pimozone with sertraline and/or
254 aripiprazole in the gastrointestinal tract, we performed a transport study with Caco-2 cells, which have
255 been widely used for experimental studies of gastrointestinal permeability. The ER of pimozone was
256 decreased significantly and the permeability was increased when sertraline or aripiprazole was co-
257 administered with pimozone, compared with the ER of pimozone alone (Fig 1B). Moreover, the ATPase
258 activity of P-gp-expressing inverted membrane vesicles was elevated in a pimozone-concentration-
259 dependent manner (Fig 2). However, the ATPase activity was reduced in the high concentration range,
260 suggesting that pimozone is both a P-gp substrate and an inhibitor at higher concentrations. Furthermore,
261 the efflux of pimozone from P-gp-overexpressing LLC-GA5-COL150 cells had both saturable and non-
262 saturable linear components (Fig 3). For the saturable carrier-mediated transport of pimozone, we
263 obtained J_{max} and K_t values of 84.9 pmol/min/mg protein and 10.6 μ M, respectively. Therefore, J_{max}/K_t ,
264 which reflects affinity for the transport carrier(s), is 8.0 μ L/min/mg protein. J_{max} and K_t of
265 Rhodamine123 (Rho123), a well-known P-gp substrate, are 988 pmol/min/mg protein and 173 μ M,
266 respectively [24], giving a J_{max}/K_t value of 5.7 μ L/min/mg protein. Therefore, the affinity of pimozone
267 for P-gp may be similar to that of Rho123, although it should be noted that the experimental method
268 and conditions were not the same in the two cases. Pimozone was transported in the B-to-A direction
269 of LLC-GA5-COL150 cell monolayers, and sertraline and aripiprazole decreased the ER of pimozone
270 by about 90% and 80%, respectively (Fig 4). In the gastrointestinal tract, the effective concentration

of pimozone is estimated to be at least 9 μ M and its K_t for P-gp was 10.6 μ M, suggesting that P-gp-mediated drug interactions could occur. Importantly, because the experimental concentrations of sertraline and aripiprazole were set based upon the clinically used doses, it is likely that P-gp-mediated drug interaction in the gastrointestinal tract could occur in clinical situations when these drugs are co-administered with pimozone.

In conclusion, pimozone is a substrate of P-gp, and its absorption is increased by sertraline and aripiprazole. Our results suggest that elevated pimozone blood levels observed when the drug is administered in combination with sertraline and/or aripiprazole can be explained at least in part by interaction at P-gp. Further in vivo studies seem warranted.

Acknowledgments

This research was supported by the Laboratory of Biopharmaceutics, Department of Pharmacology, Faculty of Pharmacy, Takasaki University of Health and Welfare, and by the Gunma Yakugakunetwork.

Conflict of interest

The authors declare that there is no conflict of interest.

289

290 **Author contributions**

291 Investigation: Hiroki Morishita, Kozue Okawa, Misaki Ishii, Kenta Mizoi, Hiroshi

292 Arakawa, Kentaro Yano.

293 Methodology: Hiroki Morishita, Kozue Okawa, Misaki Ishii.

294 Project administration: Hiroki Morishita, Kentaro Yano.

295 Supervision: Takuo Ogihara

296 Writing – original draft: Hiroki Morishita

297 Writing – review & editing: Takuo Ogihara

298

299

300 **References**

301 [1] P. Mackin, Cardiac side effects of psychiatric drugs., Hum. Psychopharmacol. 23

302 Suppl 1(2008) 3–14.

303 <https://doi.org/10.1002/hup.915> PMID: 18098218.

304 [2] J. Kang, L. Wang, F. Cai, D. Rampe, High affinity blockade of the HERG cardiac

305 K(+)channel by the neuroleptic pimoziide., Eur. J. Pharmacol. 392 (2000) 137–140.

306 [https://doi.org/10.1016/s0014-2999\(00\)00123-0](https://doi.org/10.1016/s0014-2999(00)00123-0) PMID: 10762666.

307 [3] M. Gulisano, P. V Cali, A.E. Cavanna, C. Eddy, H. Rickards, R. Rizzo,

308 Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette
309 syndrome., Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 32
310 (2011) 1213–1217.
311 <https://doi.org/10.1007/s10072-011-0678-1> PMID: 21732066.

312 [4] Product Information: ORAP® Tablet, 18th edition (2019), Astellas Pharma Inc.
313 Tokyo, Japan.
314 http://www.info.pmda.go.jp/go/pack/1179022C1034_1_11/. Last accessed
315 Jan/12/2020.

316 [5] <https://www.mhlw.go.jp/stf/shingi/2r9852000002ndoo-att/2r9852000002ndq5.pdf>.
317 Last accessed Jan/3/2020. Ministry of Health, Labour and Welfare, Japan.

318 [6] E. Spina, J. de Leon, Clinical applications of CYP genotyping in psychiatry. J.
319 Neural Transm. 122 (2015) 5–28.
320 <https://doi.org/10.1007/s00702-014-1300-5> PMID: 25200585.

321 [7] E. Spina, F. Pisani, J. de Leon, Clinically significant pharmacokinetic drug
322 interactions of antiepileptic drugs with new antidepressants and new antipsychotics.
323 Pharmacol. Res. 106 (2016) 72–86.
324 <https://doi.org/10.1016/j.phrs.2016.02.014> PMID: 26896788.

325 [8] J. Alderman, Coadministration of sertraline with cisapride or pimozide: an open-

326 label, nonrandomized examination of pharmacokinetics and corrected qt intervals in
 327 healthy adult volunteers, Clin. Ther. 27 (2005) 1050–1063.
 328 <https://doi.org/10.1016/j.clinthera.2005.07.013> PMID: 16154484.

329 [9] F. Muller, M.F. Fromm, Transporter-mediated drug-drug interactions.
 330 Pharmacogenomics. 12 (2011) 1017–1037.
 331 <https://doi.org/10.2217/pgs.11.44> PMID: 21787191.

332 [10] M. Takano, R. Yumoto, T. Murakami, Expression and function of efflux drug
 333 transporters in the intestine. Pharmacol. Ther. 109 (2006) 137–161.
 334 <https://doi.org/10.1016/j.pharmthera.2005.06.005> PMID: 16209890.

335 [11] L.Z. Benet, The drug transporter-metabolism alliance: uncovering and defining the
 336 interplay. Mol. Pharm. 6 (2009) 1631–1643.
 337 <https://doi.org/10.1021/mp900253n> PMID: 19874004.

338 [12] B.J. Gurley, A. Swain, D.K. Williams, G. Barone, S.K. Battu, Gauging the clinical
 339 significance of P-glycoprotein-mediated herb-drug interactions: comparative effects
 340 of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin
 341 pharmacokinetics. Mol. Nutr. Food Res. 52 (2008) 772–779.
 342 <https://doi.org/10.1002/mnfr.200700081> PMID: 18214850.

343 [13] J. Rengelshausen, C. Goggelmann, J. Burhenne, K.-D. Riedel, J. Ludwig, J. Weiss,

344 G. Mikus, I. Walter-Sack, W.E. Haefeli, Contribution of increased oral
345 bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-
346 clarithromycin interaction. *Br. J. Clin. Pharmacol.* 56 (2003) 32–38.
347 <https://doi.org/10.1046/j.1365-2125.2003.01824.x> PMID: 12848773; PMCID:
348 PMC1884337

349 [14] J. Weiss, S.-M.G. Dormann, M. Martin-Facklam, C.J. Kerpen, N. Ketabi-Kiyanvash,
350 W.E. Haefeli, Inhibition of P-glycoprotein by newer antidepressants., *J. Pharmacol.*
351 *Exp. Ther.* 305 (2003) 197–204.
352 <https://doi.org/10.1124/jpet.102.046532> PMID: 12649369.

353 [15] J.-S. Wang, H.-J. Zhu, B.B. Gibson, J.S. Markowitz, J.L. Donovan, C.L. DeVane,
354 Sertraline and its metabolite desmethylsertraline, but not bupropion or its three
355 major metabolites, have high affinity for P-glycoprotein., *Biol. Pharm. Bull.* 31
356 (2008) 231–234.
357 <https://doi.org/10.1248/bpb.31.231> PMID: 18239278; PMCID: PMC2666302.

358 [16] Y. Nagasaka, K. Oda, T. Iwatsubo, A. Kawamura, T. Usui, Effects of aripiprazole
359 and its active metabolite dehydroaripiprazole on the activities of drug efflux
360 transporters expressed both in the intestine and at the blood-brain barrier.,
361 *Biopharm. Drug Dispos.* 33 (2012) 304–315.

362 <https://doi.org/10.1002/bdd.1801> PMID: 22847220.

363 [17] W.A. van Vloten, Pimozide: use in dermatology., *Dermatol. Online J.* 9 (2003) 3.

364 PMID: 12639456

365 [18] T. Tomono, T. Machida, H. Kamioka, Y. Shibasaki, K. Yano, T. Ogihara, Entinostat

366 reverses P-glycoprotein activation in snail-overexpressing adenocarcinoma HCC827

367 cells. *PLoS One.* 13 (2018) e0200015.

368 <https://doi.org/10.1371/journal.pone.0200015> PMID: 29979729; PMCID:

369 PMC6034804

370 [19] T. Ogihara, M. Kamiya, M. Ozawa, T. Fujita, A. Yamamoto, S. Yamashita, S.

371 Ohnishi, Y. Isomura, What kinds of substrates show P-glycoprotein-dependent

372 intestinal absorption? Comparison of verapamil with vinblastine. *Drug Metab.*

373 *Pharmacokinet.* 21 (2006) 238–244.

374 <https://doi.org/10.2133/dmpk.21.238> PMID: 16858128.

375 [20] K. Morimoto, M. Nakakariya, Y. Shirasaka, C. Kakinuma, T. Fujita, I. Tamai, T.

376 Ogihara, Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-

377 glycoprotein., *Drug Metab. Dispos.* 36 (2008) 6–9.

378 <https://doi.org/10.1124/dmd.107.017699> PMID: 17940134.

379 [21] K. Yano, S. Takimoto, T. Motegi, T. Tomono, M. Hagiwara, Y. Idota, K. Morimoto,

380 A. Takahara, T. Ogihara, Role of P-glycoprotein in regulating cilnidipine
381 distribution to intact and ischemic brain., *Drug Metab. Pharmacokinet.* 29 (2014)
382 254–258.
383 <https://doi.org/10.2133/dmpk.dmpk-13-rg-072> PMID: 24366438.

384 [22] Food and Drug Administration. Guidance for Industry: Waiver of In Vivo
385 Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral
386 Dosage Forms Based on a Biopharmaceutics Classification System (2017).
387 <https://www.fda.gov/media/70963/download>. Last accessed Jan/13/2020.

388 [23] T. Ogihara, I. Tamai, H. Takanaga, Y. Sai, A. Tsuji, Stereoselective and carrier-
389 mediated transport of monocarboxylic acids across Caco-2 cells., *Pharm. Res.* 13
390 (1996) 1828–1832.
391 <https://doi.org/10.1023/a:1016081007981> PMID: 8987079.

392 [24] H.-J. Cho, M.-K. Choi, H. Lin, J.S. Kim, S.-J. Chung, C.-K. Shim, D.-D. Kim,
393 Expression and functional activity of P-glycoprotein in passaged primary human
394 nasal epithelial cell monolayers cultured by the air-liquid interface method for nasal
395 drug transport study., *J. Pharm. Pharmacol.* 63 (2011) 385–391.
396 <https://doi.org/10.1111/j.2042-7158.2010.01221.x> PMID: 21749386.
397

Figure

Figure

Figure

Figure